Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation (iVent)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00652756|
Recruitment Status : Withdrawn (Unable to recruit adequately)
First Posted : April 4, 2008
Last Update Posted : April 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Respiration, Artificial||Device: Use of ventilator during patient transport (Versamed iVent) Other: Bag-valve ventilation||Not Applicable|
Transporting acute-care patients who require mechanical ventilation within a hospital can be fraught with hazards. Prior studies have revealed a high level of transport-associated complications including episodes of hypertension, hypoxemia, respiratory arrest, and death (1). In many institutions, the preferred method of transporting intubated patients is to use manual ventilation with a resuscitator bag, an approach that fully occupies one member of the transport team. Using a transport ventilator involves taking an intubated patient who has been placed on one ventilator and switching the patient to the transport ventilator; until now, transport ventilators had not been designed to match the capabilities of the more robustly engineered critical care ventilators.
The use of noninvasive ventilation (NIV) to treat patients with COPD exacerbations and other forms of respiratory failure has increased because of its demonstrated efficacy in reducing the need for intubation as well as morbidity and mortality (2). None of the ventilators usually used for noninvasive ventilation was designed for in-patient transport.
Currently, the standard of care in this institution is to transport intubated patients receiving mechanical ventilation by using a manual resuscitation bag and to transport patients receiving NIV by placing the patient on oxygen therapy without ventilatory support.
The VersaMed iVent ventilator was designed to treat respiratory failure in the acute care setting. The device is suitable for patients who are intubated as well as for patients receiving noninvasive ventilation, has a backup battery so that it can function during transport, and has been approved by the FDA for invasive and noninvasive mechanical ventilation. This device permits continuity of mechanical ventilation virtually regardless of patient status.
We propose to evaluate the utility of the VersaMed iVent ventilator in the acute care setting, hypothesizing that, in comparison to the standard approach, the use of the VersaMed will facilitate transport, reduce transport-associated complications, and provide equivalent ventilatory support and transport-success rates for both intubated patients and patients receiving NIV.
- Braman SS, Dunn SM, Amico CA, Millman RP. Complications of intrahospital transport in critically ill patients. Ann Intern Med 1987; 107:469-73.
- Mehta S, Hill NS. Noninvasive ventilation-state of the art. Am J Respir Crit Care Med 2001; Feb; 163(2):540-77.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||February 2012|
Patient is placed on a transport ventilator.
Device: Use of ventilator during patient transport (Versamed iVent)
The goal of the transport ventilator is to provide optimal ventilation.
Other Name: Versamed iVent ventilator
Patient is ventilated using the current standard at this institution.
Other: Bag-valve ventilation
Use of bag-valve ventilation during patient transport.
Other Name: Use of manual resuscitator during transport.
- To determine whether using a ventilator during patient transport has better outcomes than the current approach to transport. [ Time Frame: One year (estimated) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652756
|United States, Massachusetts|
|Tufts Medical Center|
|Boston, Massachusetts, United States, 01770|
|Principal Investigator:||Nicholas S. Hill, MD||Tufts Medical Center|